REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
8.69
+0.07 (0.81%)
At close: Apr 28, 2026, 4:00 PM EDT
8.70
+0.01 (0.12%)
After-hours: Apr 28, 2026, 7:56 PM EDT
REGENXBIO Employees
REGENXBIO had 371 employees as of December 31, 2025. The number of employees increased by 18 or 5.10% compared to the previous year.
Employees
371
Change (1Y)
18
Growth (1Y)
5.10%
Revenue / Employee
$459,410
Profits / Employee
-$522,582
Market Cap
448.55M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| Neurogene | 131 |
| Aura Biosciences | 113 |
| Larimar Therapeutics | 71 |
| Candel Therapeutics | 55 |
| Atea Pharmaceuticals | 55 |
| Contineum Therapeutics | 51 |
| Eupraxia Pharmaceuticals | 49 |
RGNX News
- 4 weeks ago - SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD - PRNewsWire
- 6 weeks ago - Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals - Benzinga
- 6 weeks ago - Regenxbio's Duchenne gene therapy shows improved muscle function in trial - Reuters
- 6 weeks ago - REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 - PRNewsWire
- 7 weeks ago - REGENXBIO Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts
- 7 weeks ago - REGENXBIO Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - FDA reversals leave investors worrying about the fates of other experimental drugs - CNBC
- 7 weeks ago - RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST - PRNewsWire